Compare BridgeBio Pharma Inc (BBIO) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Quantum Computing Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Quantum Computing Inc trades at $9.01 (market cap $2.07B). The key difference: BridgeBio Pharma Inc is far larger — about 8× Quantum Computing Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | QUBT | |
|---|---|---|
Market Cap | $16.61B | $2.07B |
Sector | Health | Technology |
52-Week High | $90.17 | $24.62 |
52-Week Low | $47.29 | $6.31 |
Enterprise Value | $18.16B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
QUBT trades at $9.18, up 4.62% today, amid a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $5.6 million, a significant increase from the prior year, but posted a net loss. Analyst consensus is strongly bullish with a $21.33 price target, though high valuation multiples and negative margins highlight financial challenges. Recent news includes the strategic acquisition of NHanced Semiconductors, expanding manufacturing capabilities.
The outlook is speculative with substantial growth potential in quantum computing, but high execution risk persists. Investment appeal hinges on commercial traction and margin improvement, while risks include cash burn, competitive pressures, and ongoing losses. The stock offers high upside if execution succeeds, but volatility is expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
